Human AM/AMBP-1 Attenuates Renal Ischemia/Reperfusion Injury in the Rat
Kavin G. Shah,Derry Rajan,Rongqian Wu,Kambhampaty Krishnasastry,Jeffrey Nicastro,Ernesto P. Molmenti,Gene F. Coppa,Ping Wang
DOI: https://doi.org/10.1016/j.jss.2009.11.485
IF: 2.417
2010-01-01
Journal of Surgical Research
Abstract:Introduction: Acute renal failure secondary to ischemia/reperfusion (I/R) injury poses a significant burden on both surgeons and patients. It carries a high morbidity and mortality rate and no specific treatment currently exists. Significant causes of renal I/R injury include trauma, sepsis, hypoperfusion, and various surgical procedures. Adrenomedullin (AM) is a novel vasoactive peptide and adrenomedullin binding protein-1 (AMBP-1) is a specific AM binding protein which augments the activity of AM. We have demonstrated that AM combined with AMBP-1 is beneficial in various disease conditions. However, it remains unknown whether human AM/AMBP-1 provides any beneficial effects in renal I/R injury. Objective: To determine if administration of human AM/AMBP-1 can prevent and/or minimize damage in a rat model of renal I/R injury. Methods: Male adult rats were subjected to bilateral renal pedicle clamping with microvascular clips for 60 min. Administration of either vehicle (normal saline) or human AM (12 μg/kg) and AMBP-1 (40 μg/kg) was given intravenously over 30 min immediately following clip removal (i.e., reperfusion). Rats were allowed to recover for 24 h post treatment, and then sacrificed for sampling. Blood was collected and measured for systemic markers of tissue injury and inflammation. Renal samples were harvested for water content and TNF-α analysis. Results: Systemic markers of tissue injury were significantly increased following renal I/R and infusion of normal saline. As shown in the table below, plasma creatinine and BUN levels were markedly elevated as compared to sham animals. Renal water content was also significantly increased. Furthermore, liver injury markers AST and ALT, as well as TNF-α levels, were elevated after renal I/R. Administration of human AM/AMBP-1 decreased plasma levels of creatinine by 64% following renal I/R as compared to vehicle infused animals, and serum levels of BUN decreased by 47% in the treatment group. Human AM/AMBP-1 significantly decreased the renal water content, and plasma levels of AST and ALT showed a 26% and a 32% reduction, respectively, following treatment. Furthermore, treatment with human AM/AMBP-1 reduced the pro-inflammatory cytokine TNF-α by 20% in the serum. Renal tissue TNF-α levels (pg/mg protein) were reduced by 23% (2035±175 in AM/AMBP-1 vs. 2653±245 in vehicle; p<0.05, n=6; Sham=667±125). A Western blot analysis of serum AMBP-1 was conducted and resulted in a significant decrease in animals post renal I/R injury, down from 4.6±0.5 to 2.1±0.6 (arbitrary unit; p<0.05, n=4), suggesting that the decreased AMBP-1 levels may play an important role in renal I/R injury. Conclusion: Administration of human AM/AMBP-1 significantly decreased systemic markers of tissue injury and inflammation after renal I/R. Therefore, human AM combined with AMBP-1 may be developed as a novel treatment in patients following renal I/R injury.